HighQC™ Human IPSC-Derived Microglia
0.01 EURAsk for quotation
On request
quantity
Produktdetaljer
Katalognummer: 870 - ABC-SC2110
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 1 vial
ABC-SC2110
HighQC™ Human IPSC-Derived Microglia
Human iPSC-derived Microglia are generated using a fully defined medium from a factory of human iPSC-derived monocytes. These highly validated Human iPSC-derived Microglia have been successfully used in multiple applications to evaluate functionality such as assessment for cytokine secretion by ELISA, phagocytosis capability by phagocytosis and efferocytosis assays, and changes in the production of reactive oxygen species (ROS) by ROS assays. Human iPSC-derived Microglia reveals the expression of key microglia-specific markers, such as transmembrane protein 119 (TMEM119) and Purinergic Receptor P2Y12 (P2RY12), and the myeloid markers TREM2 and IBA-1.
Ask for quotation
ABC-SC0067T
HighQC™ Human IPSC-Derived Neural Stem Cell LRRK2 G2019S HOM
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGCandgt;AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Ask for quotation
ABC-SC0068T
HighQC™ Human IPSC-Derived Neural Stem Cell LRRK2 G2019S HET
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGCandgt;AGC) in the LRRK2 gene. This line is heterozygous for the G2019S mutation where one allele contains the mutation and the other allele is wild type at the locus.The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Ask for quotation
ABC-SC0069T
HighQC™ Human IPSC-Derived Neural Stem Cell MAPT R406W HOM
Human Human IPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the R406W mutation (CGGandgt;TGG) into the MAPT gene. This line is homozygous for the R406W mutation so both alleles contain the mutation. The R406W mutation in MAPT has been implicated in familial frontotemporal dementia and parkinsonism (Hutton et al., 1998; Behnam et al., 2015) and has been seen in patients with clinical presentation resembling Alzheimer's disease (Rademakers et al., 2003; Lindquist et al., 2008). The R406W mutation reduces the ability of MAPT/tau to bind to microtubules in vitro (Hong et al., 1998).